Thorsten G.
- Country
- Germany
- Department
- Institut für Klinisch-Onkologische Forschung
Research Overview
- Evaluation of the Safety, Tolerability, and Efficacy of the Pan-KRAS Inhibitor LY4066434 in Patients with KRAS Mutant Advanced Solid Tumors
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
- Phase Ib Evaluation of Neoadjuvant Tislelizumab Plus FLOT in Resectable Esophagogastric Adenocarcinoma
Data & Insights
Has run more than one trial at 563 of 910 partner sites.
Specializations
Gastrointestinal Cancer Research
The investigator specializes in studying advanced treatments for gastrointestinal cancers, with particular focus on colorectal cancer and esophagogastric adenocarcinoma.
- Metastatic Colorectal Cancer Treatment
- Esophagogastric Junction Tumors
- Pancreatic Cancer Therapies
Expertise includes novel therapeutic approaches combining immunotherapy with conventional treatments.
Hepatobiliary Oncology
Focuses on innovative treatments for liver and biliary tract cancers, including research into targeted therapies for hepatocellular carcinoma and cholangiocarcinoma.
- Advanced Hepatocellular Carcinoma
- Intrahepatic Cholangiocarcinoma
- Biliary Tract Malignancies
Specializes in molecular targeted therapies and immunotherapy combinations.
Thoracic Oncology
Conducts research in lung cancer treatment modalities, with emphasis on non-small cell lung cancer and novel maintenance therapy approaches.
- Advanced/Metastatic NSCLC
- Maintenance Therapy Strategies
- Immunotherapy Combinations
Investigates innovative combination therapies incorporating immunotherapy agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.